AstraZeneca Tests Biosimilar Waters Through Bevacizumab JV
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca and Japan's Fujifilm Kyowa Kirin Biologics have signed an agreement to set up a UK-based joint venture to develop globally a biosimilar version of bevacizumab, marking the first tentative step into the biosimilars sector by the research-based pharma giant.